all stories

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Fadingsecond windCoverage went quiet for 3 days, then returned with 60 more reports - 40 voices in all.
After publishing: 4 headlines quietly rewritten, 1 description edited5 changes
  1. Times of Indiaseen 21 Aug, 17:42headline rewritten

    Lip plumpers, collagen and more: How is Ozempic boosting a new beauty marketLip plumpers, collagen & more: How Ozempic is boosting a new beauty market

  2. El Mundo (Spain)seen 22 Aug, 02:51headline rewritten

    ¿Es exagerado llamar a la berberina el Ozempic natural?El fenómeno de la berberina: ¿realmente funciona como un Ozempic natural o hay exageración?

  3. ABC (Spain)seen 23 Aug, 05:07headline rewritten

    Post-Ozempic: una pastilla que adelgaza e imita los beneficios del ejercicioLa pastilla que adelgaza e imita los beneficios del ejercicio

  4. sbs.com.auseen 25 Aug, 22:29description edited
    what the description said, before and after

    We went looking into Australia's weight-loss drug boom. What we found was a market operating outside the prescription system.

    Below the surface of Australia's weight-loss drug boom, a market operates outside the prescription system.

  5. vendingmarketwatch.comseen 3 Sept, 03:26headline rewritten

    GLP-1 food trends reshape snacking and small meal choicesGLP-1 users shift toward protein-rich snacks and smaller meals

original reportingcopies
Wed, 5 August 2026peak 6 reports on Mon, 24 August 2026Fri, 4 September 2026

What it is about

Novo NordiskMarketWatchEuropeEli LillyCNBCFierce PharmaThe EconomistDrug AdministrationTamas HorvathMedicine At Yale School Of MedicineU.S.Gretel SchuellerAmericansAmericanNovo Nordisk-Eli LillyScientistsScienceAlertScienceDailyYaleNewsNOVA studija

Who published it, and when

original reportcopyedited after publishingfirst to report
Google News - Europe query1 original report
Google News - Top Stories2 original reports1 original report2 original reports1 original report1 original report2 original reports
foreignpolicyjournal.com1 original report
bakeryandsnacks.com1 original report
The Hill1 original report1 original report1 original report
wkbw.com1 original report1 copy echoing wxyz.com
Le Figaro (France)1 original report
Index.hr (Croatia)1 original report1 original report
derstandard.at1 original report
news24.com1 original report
foodmanufacture.co.uk1 original report
confectionerynews.com1 original report
fool.com1 original report2 original reports
El Mundo (Spain)2 original reports - edited after publishing1 original report
yahoo.com1 original report1 original report
ABC (Spain)1 original report - edited after publishing
Times of India1 original report - edited after publishing
wxyz.com1 original report
5 Aug, 16:52over 30 days4 Sept, 11:17

+ 24 more outlets

How it spread - 60 original reports, 3 reprints

  1. Wed, 5 August 2026

    1 report
  2. Thu, 6 August 2026

    2 reports
    • Google News - Top Stories13:45

      The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBC Lilly climbs, Novo falls as obesity drug battle intensifies BioPharma Dive Lilly confident in slow and steady Foundayo launch, as ex-US sales shine BioSpace How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? MarketWatch Novo takes another shot at Lilly The Economist

    • Google News - Top Stories13:45

      The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBC Lilly climbs, Novo falls as obesity drug battle intensifies BioPharma Dive How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? MarketWatch Lilly confident in slow and steady Foundayo launch, as ex-US sales shine BioSpace Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom Fierce Pharma

  3. Mon, 10 August 2026

    1 report
  4. Tue, 11 August 2026

    1 report
  5. Wed, 12 August 2026

    1 report
    • The Hill16:19

      Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly's lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss "hack." Those entities falsely claim their drugs are for “research-use only” when...

  6. Thu, 13 August 2026

    2 reports
  7. Sat, 15 August 2026

    2 reports
    • Google News - Top Stories02:04

      GLP-1s May Be Working in an Entirely Different Way Than We Thought ScienceAlert Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways ScienceDaily New study may change how we think about GLP-1s YaleNews GLP-1 obesity drugs activate hunger neurons to drive fat loss 동아사이언스 New Weight Loss Pills Barely Worked in Mice Until Scientists Uncovered a Brain Circuit Controlling Cravings Medical Daily

    • Index.hr (Croatia)20:17

      NOVA studija otkriva da Ozempic djeluje i putem "neurona gladi" koji potiču tijelo na aktivnije trošenje masnih zaliha i dugoročno mršavljenje.

  8. Sun, 16 August 2026

    1 report
  9. Mon, 17 August 2026

    1 report
  10. Tue, 18 August 2026

    3 reports
  11. Wed, 19 August 2026

    2 reports
  12. Thu, 20 August 2026

    4 reports
    • Google News - Top Stories12:53

      Wegovy and Zepbound are changing how Americans get health care USA Today GLP-1s are forcing a strategic reset across healthcare: Wells Fargo report Fierce Healthcare Researchers find new benefits, risks in GLP-1 weight loss drugs WAFB How GLP-1 weight loss drugs are reshaping the healthcare industry Fox Business Scientists Are Discovering Unexpected Benefits of GLP-1 Drugs SciTechDaily

    • Google News - Top Stories13:05

      How GLP-1 weight loss drugs are reshaping the healthcare industry Fox Business Wegovy and Zepbound are changing how Americans get health care USA Today Researchers find new benefits, risks in GLP-1 weight loss drugs WAFB Scientists Are Discovering Unexpected Benefits of GLP-1 Drugs SciTechDaily Beyond GLP-1s: Combination Therapy, New Hormones Reshape Obesity Treatment Yale Medicine

    • yahoo.com21:05

      Can anyone challenge Eli Lilly in the weight loss space?

    • ABC (Spain)22:45edited after publishing

      previouslyPost-Ozempic: una pastilla que adelgaza e imita los beneficios del ejercicio

      Durante décadas, adelgazar con un tratamiento parecía más una promesa que una realidad, casi como la ilusión que se vendía con las cremas antiedad. Hasta que llegaron Ozempic y otros medicamentos de la familia GLP-1. El mundo ahora se divide entre los que pierden peso con un pinchazo y los que siguen esforzándose con dieta y ejercicio. Pero si conoce a alguien en tratamiento, sabrá que perder peso con estos fármacos tampoco es tan sencillo. Muchos abandonan la medicación por sus efectos...

  13. Fri, 21 August 2026

    2 reports
    • Times of India04:57edited after publishing

      previouslyLip plumpers, collagen and more: How is Ozempic boosting a new beauty market

      Weight-loss drugs are creating new demands in beauty and nutrition sectors. Companies are developing products to address nutritional gaps and emerging beauty concerns. Nestle and Tata Consumer are preparing protein and fiber-rich offerings for these consumers. Beauty brands are promoting makeup alternatives to cosmetic procedures for users. This trend is driven by pharmaceutical advancements and growing patient bases.

    • wxyz.com15:03

      Vanderbilt researchers are studying whether GLP-1 drugs used for diabetes and obesity can help prevent opioid relapse.

      2 reprints
  14. Sat, 22 August 2026

    1 report
  15. Sun, 23 August 2026

    3 reports
    • DW Top Stories09:20

      Obesity rates climbed in the US for years, but now there are signs this could be changing. Use of weight-loss drugs such as Ozempic and Wegovy has increased rapidly — are they helping?

    • juneauempire.com15:30

      In the ongoing debate surrounding America’s metabolic crisis, we have reached a bizarre cultural paradox. On one side, we are witnessing the medicalization of appetite: millions of adults are turning to GLP-1 receptor agonists like Ozempic and Wegovy to synthetically force their bodies into feeling full. On the other, public health dialogue remains stubbornly fixated on lecturing individuals about willpower.

    • sbs.com.au19:48edited after publishing

      Below the surface of Australia's weight-loss drug boom, a market operates outside the prescription system.

  16. Mon, 24 August 2026

    6 reports
    • sci.news17:31

      Scientists have identified a decades-old chemical compound as a promising new candidate for treating obesity and related metabolic diseases.

    • The Hill18:53

      From unexpected babies to "Ozempic teeth," the ultra-popular class of GLP-1 medications are turning out to have a few unanticipated side effects. Emerging research shows the drugs, which have proven effective in treating obesity and diabetes, may also be useful in treating addiction.

    • iheart.com20:04

      GLP-1 medications, like Ozempic and Wegovy, may treat addiction by reducing cravings. A study shows they lower the risk of substance use disorders and severe harm. Researchers suggest clinical trials to explore this potential further.

    • iheart.com20:04

      GLP-1 medications, like Ozempic and Wegovy, may treat addiction by reducing cravings. A study shows they lower the risk of substance use disorders and severe harm. Researchers suggest clinical trials to explore this potential further.

    • iheart.com20:04

      GLP-1 medications, like Ozempic and Wegovy, may treat addiction by reducing cravings. A study shows they lower the risk of substance use disorders and severe harm. Researchers suggest clinical trials to explore this potential further.

    • iheart.com20:04

      GLP-1 medications, like Ozempic and Wegovy, may treat addiction by reducing cravings. A study shows they lower the risk of substance use disorders and severe harm. Researchers suggest clinical trials to explore this potential further.

  17. Tue, 25 August 2026

    5 reports
  18. Fri, 28 August 2026

    3 reports
  19. Sun, 30 August 2026

    2 reports
  20. Mon, 31 August 2026

    5 reports
  21. Tue, 1 September 2026

    4 reports
  22. Wed, 2 September 2026

    4 reports
  23. Thu, 3 September 2026

    3 reports
    • Google News - Top Stories09:00

      GLP-1 medications may worsen or speed hair loss in some men, study finds NBC News Diabetic GLP-1 use linked to increased hair loss risk Penn Today Possible Side Effect for Men on GLP-1s: Baldness Newser Genes May Explain Hair Loss in Men on Wegovy, Ozempic Seoul Economic Daily Fat jabs like Wegovy or Mounjaro can spark hair loss in men, scientists warn The Sun

    • Google News - Top Stories13:04

      Possible Side Effect for Men on GLP-1s: Baldness Newser Genes May Explain Hair Loss in Men on Wegovy, Ozempic Seoul Economic Daily Some Hair Loss in Men Is Linked to Use of Weight Loss Drugs morningstar.com Why Your Hair Might Be Thinning on a GLP-1 Drug—and What To Do About It Yahoo Health Diabetic GLP-1 use linked to increased hair loss risk Penn Medicine

    • phillyvoice.com20:42

      This research provides evidence to a side effect that had been reported anecdotally.

  24. Fri, 4 September 2026

    1 report

One email a week

The stories everytrace watched stay alive - how many independent outlets carried each one, and how long it lasted. No daily digest, no breaking-news alerts.